A Study of MRG003 in Combination With Pucotenlimab Versus Chemotherapy in the Treatment of Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma

This study is comparing a combination of MRG003 (an antibody-drug conjugate that delivers chemotherapy directly to EGFR-expressing cancer cells) plus pucotenlimab (an immune checkpoint drug) against standard chemotherapy in people with nasopharyngeal carcinoma (NPC) — a type of head and neck cancer — that has come back or spread. **You may be eligible if...** - You have confirmed recurrent or metastatic nasopharyngeal carcinoma - Your cancer has progressed after at least one prior treatment - You have at least one measurable tumor - Your physical performance score is ECOG 0 or 1 - Your heart pumping function (LVEF) is 50% or higher **You may NOT be eligible if...** - You have uncontrolled brain metastases - You have serious heart, liver, kidney, or coagulation problems - You have had severe allergic reactions to similar drugs - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.